Cargando…

A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX

Detalles Bibliográficos
Autores principales:	Tung, F, Tung, J, Fischl, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441395/ http://dx.doi.org/10.1186/1742-4690-9-S2-P127

Ejemplares similares

P19-38. Safety and protective immunity in Rhesus monkeys immunized with replication-defective HIV/SIV vaccine
por: Tung, F, et al.
Publicado: (2009)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Some small sample properties of the EWOC design in dose escalation trials
por: Kinnersley, Nelson
Publicado: (2015)

160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age
por: Chang, Leejah, et al.
Publicado: (2020)

Phase I clinical trials of safety and immunogenicity of live cultural influenza vaccine vector-flu
por: Nechaeva, Elena A, et al.
Publicado: (2015)

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans?
por: Wahren, B, et al.
Publicado: (2006)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
por: Nemunaitis, John, et al.
Publicado: (2013)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
por: van Montfort, Thijs, et al.
Publicado: (2011)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Addressing the barriers to implementing model based designs in dose escalation studies
por: Cornelius, Victoria, et al.
Publicado: (2015)

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
por: Lewis, DJ, et al.
Publicado: (2009)

Yeast surface display of HIV Env protein variants for the discovery of novel vaccine immunogens
por: Grimm, S, et al.
Publicado: (2012)

P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
por: Zhang, C, et al.
Publicado: (2009)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
por: Borthwick, NJ, et al.
Publicado: (2012)

Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine
por: Ren, X, et al.
Publicado: (2012)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
por: Regan, Courtney, et al.
Publicado: (2015)

P11-18. Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV
por: Gunderson, S, et al.
Publicado: (2009)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors
por: Zhang, X, et al.
Publicado: (2012)

Breadth or conservation score (CS): which is more important for HIV-1 T cell based vaccine immunogen design?
por: Kunwar, P, et al.
Publicado: (2012)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

P19-01. Pre-clinical immunogenicity of mosaic Asian AE/B HIV-1 DNA vaccine in mice
por: Sirivichayakul, S, et al.
Publicado: (2009)

P18-07. Ex vivo production of autologous HIV-1 to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (clinical trial DCV02)
por: Gil, C, et al.
Publicado: (2009)

A novel Bayesian method for dual-agent Phase I dose-escalation studies using penalized D-optimality
por: Wheeler, Graham
Publicado: (2013)

Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial
por: Mo, Zhao-Jun, et al.
Publicado: (2023)

A minimal T-cell immunogen designed to cover HIV-1 specificities associated with control is immunogenic in mice and breaks CTL immunodominance
por: Mothe, B, et al.
Publicado: (2012)

P15-06. Brighton collaboration viral vector vaccines safety working group (V3SWG): maximizing the comparability and value of safety data from HIV vaccine trials
por: Chen, RT, et al.
Publicado: (2009)

Evaluation of a replication-competent VSV-SIV vaccine candidate
por: Jurgens, CK, et al.
Publicado: (2012)

An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1
por: Dutton, Julie L., et al.
Publicado: (2016)

A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
por: Slingluff, Craig L, et al.
Publicado: (2014)

Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients
por: Lagler, H, et al.
Publicado: (2010)

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials
por: Wheeler, Graham, et al.
Publicado: (2015)

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t32hg11jg2uktrioohd6qts017